Nicole Merten

Nicole Merten

Auto-generated profile, based on publicly available information

Nicole Merten

Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Nussallee 6, Bonn 53115, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCaroline Coombs
Caroline Coombs
AGAntonios Georgantzoglou
Antonios Georgantzoglou
HWHazel A. Walker
Hazel A. Walker
JPJulian Patt
Julian Patt
NMNicole Merten
Nicole Merten
MSMilka Sarris
Milka Sarris
Immune cells congregate at specific loci to fight infections during inflammatory responses, a process that must be transient and self-resolving. Cell dispersal promotes resolution, but it remains unclear how transition from clustering to dispersal is regulated. Here we show, using quantitative live imaging in zebrafish, that differential ligand-induced trafficking of chemokine receptors such as Cxcr1 and Cxcr2 orchestrates the state of neutrophil congregation at sites of tissue damage. Through receptor mutagenesis and biosensors, we show that Cxcr1 promotes clustering at wound sites, but is promptly desensitized and internalized, which prevents excess congregation. By contrast, Cxcr2 promotes bidirectional motility and is sustained at the plasma membrane. Persistent plasma membrane residence of Cxcr2 prolongs downstream signaling and is required for sustained exploratory motion conducive to dispersal. Thus, differential trafficking of two chemokine receptors allows coordination of antagonistic cell behaviors, promoting a self-resolving migratory response.

27 January 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MHMax Erhard Huber
Max Erhard Huber
LTLara Toy
Lara Toy
MSMaximilian Franz Schmidt
Maximilian Franz Schmidt
HVHannah Vogt
Hannah Vogt
JBJulian Budzinski
Julian Budzinski
MSMatthias Schiedel
Matthias Schiedel
A conserved intracellular allosteric binding site (IABS) has recently been identified at several G protein‐coupled receptors (GPCRs). Starting from vercirnon, an intracellular C−C chemokine receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease, we developed a chemical biology toolbox targeting the IABS of CCR9. We first synthesized a fluorescent ligand enabling equilibrium and kinetic binding studies via NanoBRET as well as fluorescence microscopy. Applying this molecular tool in a membrane‐based setup and in living cells, we discovered a 4‐aminopyrimidine analogue as a new intracellular CCR9 antagonist with improved affinity. To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs. In a proof‐of‐principle study, we succeeded in showing that our CCR9‐PROTAC is able to reduce CCR9 levels, thereby offering an unprecedented approach to modulate GPCR activity.

19 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TBTobias Benkel
Tobias Benkel
MZMirjam Zimmermann
Mirjam Zimmermann
JZJulian Zeiner
Julian Zeiner
SBSergi Bravo
Sergi Bravo
NMNicole Merten
Nicole Merten
EKEvi Kostenis
Evi Kostenis
Carvedilol is among the most effective β-blockers for improving survival after myocardial infarction. Yet the mechanisms by which carvedilol achieves this superior clinical profile are still unclear. Beyond blockade of β1-adrenoceptors, arrestin-biased signalling via β2-adrenoceptors is a molecular mechanism proposed to explain the survival benefits. Here, we offer an alternative mechanism to rationalize carvedilol’s cellular signalling. Using primary and immortalized cells genome-edited by CRISPR/Cas9 to lack either G proteins or arrestins; and combining biological, biochemical, and signalling assays with molecular dynamics simulations, we demonstrate that G proteins drive all detectable carvedilol signalling through β2ARs. Because a clear understanding of how drugs act is imperative to data interpretation in basic and clinical research, to the stratification of clinical trials or to the monitoring of drug effects on the target pathway, the mechanistic insight gained here provides a foundation for the rational development of signalling prototypes that target the β-adrenoceptor system.

18 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MHMax E. Huber
Max E. Huber
SWSilas Wurnig
Silas Wurnig
LTLara Toy
Lara Toy
CWCorinna Weiler
Corinna Weiler
NMNicole Merten
Nicole Merten
MSMatthias Schiedel
Matthias Schiedel
Herein, we report the structure-based development of fluorescent ligands targeting the intracellular allosteric binding site (IABS) of CXC chemokine receptor 2 (CXCR2), a G protein-coupled receptor (GPCR) that has been pursued as a drug target in oncology and inflammation. Starting from the cocrystallized intracellular CXCR2 antagonist 00767013 (1), tetramethylrhodamine (TAMRA)-labeled CXCR2 ligands were designed, synthesized, and tested for their suitability as fluorescent reporters to probe binding to the IABS of CXCR2. By means of these studies, we developed Mz438 (9a) as a high-affinity and selective fluorescent CXCR2 ligand, enabling cell-free as well as cellular NanoBRET-based binding studies in a nonisotopic and high-throughput manner. Further, we show that 9a can be used as a tool to visualize intracellular target engagement for CXCR2 via fluorescence microscopy. Thus, our small-molecule-based fluorescent CXCR2 ligand 9a represents a promising tool for future studies of CXCR2 pharmacology.

1 November 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NBNader M. Boshta
Nader M. Boshta
MLMichael Lewash
Michael Lewash
MKMeryem Köse
Meryem Köse
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
SSSoumya Sarkar
Soumya Sarkar
CMChrista Müller
Christa Müller

12 February 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SWSilas L. Wurnig
Silas L. Wurnig
MHMax E. Huber
Max E. Huber
CWCorinna Weiler
Corinna Weiler
HBHanna Baltrukevich
Hanna Baltrukevich
NMNicole Merten
Nicole Merten
FHFinn K. Hansen
Finn K. Hansen
Intracellular ligands of G protein-coupled receptors (GPCRs) are gaining significant interest in drug discovery. Here, we report the development of the fluorescent ligand Mz437 (4) targeting the CC chemokine receptor CCR7 at an intracellular allosteric site. We demonstrate its experimental power by applying 4 to identify two improved intracellular CCR7 antagonists, SLW131 (10) and SLW132 (21m), developed by converting two weakly active antagonists into single- or double-digit nanomolar ligands with minimal modifications. The thiadiazoledioxide 10 was derived from the CCR7 antagonist Cmp2105 by removing a methyl group from the benzamide moiety, while the squaramide 21m was obtained from the CXCR1/CXCR2 antagonist and clinical candidate navarixin by replacing the ethyl substituent by a tert-butyl group to engage a lipophilic subpocket. We show that 10 and 21m qualify to probe CCR7 biology in recombinant and primary immune cells and expect our novel probes to facilitate the design of next-generation intracellular CCR7 ligands.